The Experts below are selected from a list of 3474 Experts worldwide ranked by ideXlab platform
Barry N. Lutsky - One of the best experts on this subject based on the ideXlab platform.
-
Effects of treatment with Mometasone Furoate dry powder inhaler in children with persistent asthma.
Annals of allergy asthma & immunology : official publication of the American College of Allergy Asthma & Immunology, 2006Co-Authors: William E. Berger, Paul Chervinsky, Henry Milgrom, Michael Noonan, Steven Weinstein, Barry N. Lutsky, Heribert StaudingerAbstract:Background Mometasone Furoate dry powder inhaler (DPI) has been shown to effectively treat asthma in children. Objective To evaluate the efficacy and safety of 2 dosing regimens of Mometasone Furoate DPI in the treatment of mild-to-moderate persistent asthma in children previously using inhaled corticosteroids (ICSs). Methods A 12-week, multicenter, double-blind, parallel-group, placebo-controlled study evaluated 2 dosing regimens of Mometasone Furoate DPI (100 μg every evening and 100 μg twice daily) in 296 children 4 to 11 years old with asthma previously using ICSs. The primary efficacy variable was the change in percentage of predicted forced expiratory volume in 1 second (FEV 1 ) from baseline to end point. Secondary efficacy variables included absolute FEV 1 , forced expiratory flow between 25% and 75% , forced vital capacity, morning and evening peak expiratory flow, asthma symptom scores, albuterol use, nocturnal awakenings, response to therapy, and health-related quality of life. Results Mean changes from baseline at end point in predicted FEV 1 were 4.73 and 5.52 percentage points for Mometasone Furoate DPI, 100 μg every evening and 100 μg twice daily, respectively, the difference of which was not significant, and −1.77 percentage points for placebo ( P ≤ .002). Significant improvements in secondary efficacy variables were also observed for both Mometasone Furoate DPI treatments over placebo. Both Mometasone Furoate DPI doses were well tolerated, and no significant differences were noted among the 3 treatment groups in adverse event reporting. Conclusions Both Mometasone Furoate DPI doses were well tolerated and significantly improved lung function, maintained effective asthma control, and improved quality of life in children with asthma.
-
Once-daily evening administration of Mometasone Furoate in asthma treatment initiation
Annals of allergy asthma & immunology : official publication of the American College of Allergy Asthma & Immunology, 2006Co-Authors: George W. Bensch, Robert B. Berkowitz, Bruce M. Prenner, Stanley P. Galant, Joe W. Ramsdell, Barry N. LutskyAbstract:Background In a previous study, a 200-μg once-daily evening dose of Mometasone Furoate dry powder inhaler (DPI) was effective in patients with asthma previously taking inhaled corticosteroids. No studies have been conducted to test the effect of a once-daily evening dose in patients previously using only short-acting β 2 -adrenergic agonists (SABAs) for symptom relief. Objective To evaluate the effectiveness of Mometasone Furoate DPI administered once daily in the evening as initial controller therapy in patients previously using SABAs alone for asthma. Methods Patients with mild-to-moderate persistent asthma from 18 US centers participated in a 12-week, randomized, double-blind, placebo-controlled study. Patients received either Mometasone Furoate DPI, 200 μg, or placebo once daily in the evening. The primary efficacy variable was the change in forced expiratory volume in 1 second from baseline to the end point (last evaluable visit). Other measurements included forced vital capacity, forced expiratory flow between 25% and 75%, morning and evening peak expiratory flow, asthma symptoms, use of albuterol, nocturnal awakenings, physicians' evaluation of response to therapy, and time to asthma worsening. Results At the end point, the mean increase in forced expiratory volume in 1 second relative to baseline for the Mometasone Furoate DPI group of 0.43 L (16.8%) was significantly greater than that for the placebo group of 0.16 L (6.0%) ( P P Conclusion Mometasone Furoate DPI (200 μg) administered once daily in the evening significantly improves pulmonary function in patients previously using SABAs alone for asthma control.
-
comparison of once daily Mometasone Furoate nasonex and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis
Annals of Allergy Asthma & Immunology, 1997Co-Authors: Michael Mandl, Keith B Nolop, Barry N. LutskyAbstract:Background Mometasone Furoate (Nasonex), in a new once daily aqueous nasal spray formulation, has been shown to be as effective and well tolerated as twice daily beclomethasone dipropionate aqueous nasal spray in treating symptoms of seasonal allergic rhinitis and perennial rhinitis. Objective To compare the effectiveness and tolerability of Mometasone Furoate to placebo and to fluticasone propionate aqueous nasal spray, all treatments administered once daily, in patients with perennial rhinitis. Methods This was a 3-month, randomized, double-blind, double dummy, parallel group study in 550 patients, aged 12 to 77 years, at 25 centers in Canada, Latin America, and Europe. Patients allergic to at least one perennial allergen, with confirmed allergy history, skin test positivity, and moderate to severe symptomatology, were eligible to receive one of the following treatments, once daily in the morning: Mometasone Furoate 200 micrograms, fluticasone propionate 200 micrograms, or placebo. The primary efficacy variable was the change from baseline in total am plus pm diary nasal symptom score over the first 15 days of treatment. Results Four hundred fifty-nine patients were valid for efficacy. For the primary efficacy variable, Mometasone Furoate was significantly ( P .01) more effective than placebo and was not statistically different from fluticasone propionate (percent reductions from baseline were 37, 39, and 22 for Mometasone Furoate, fluticasone propionate, and placebo, respectively). Generally, similar trends were seen for physician-evaluated total nasal symptoms, and patient-rated and physician-rated overall condition and response to therapy. Overall, Mometasone Furoate was at least as effective as fluticasone propionate at equivalent doses. There was no evidence of tachyphylaxis. All treatments were well tolerated. Conclusion Mometasone Furoate and fluticasone propionate adequately controlled symptoms of perennial rhinitis and were well tolerated.
-
once daily Mometasone Furoate aqueous nasal spray nasonex in seasonal allergic rhinitis an active and placebo controlled study
Allergy, 1996Co-Authors: Jacques Hebert, Keith B Nolop, Barry N. LutskyAbstract:Mometasone Furoate aqueous nasal spray (Nasonex) was compared with beclomethasone dipropionate (BDP) aqueous nasal spray in a double-blind, randomized, placebo-controlled, double-dummy, parallel-group study of adults with moderate to severe seasonal allergic rhinitis. Patients allergic to at least one tree and/or grass aeroallergen received one of the following regimens for up to 4 weeks; Mometasone Furoate 100 micrograms once daily [OD] (n = 126) or 200 micrograms OD (n = 126), BDP 200 micrograms twice daily (n = 126), or only placebo spray (n = 123). Physician-rated nasal and total symptom scores, and global evaluation of overall condition and therapeutic response by physicians and patients, showed that the three active treatments were equally effective, and all three were significantly superior to placebo at most time points. Overall, Mometasone Furoate 200 micrograms OD demonstrated somewhat greater numerical, but not statistical, superiority to Mometasone Furoate 100 micrograms OD at the earliest evaluation time point. At the end of treatment, complete or marked relief was obtained in 77% of patients with Mometasone Furoate 100 micrograms/day, 79% with Mometasone Furoate 200 micrograms/day, and 74% with BDP, compared with 54% of placebo vehicle control patients. Mometasone Furoate and BDP were equally well tolerated. It was concluded that Mometasone Furoate adequately controls symptoms of moderate to severe seasonal allergic rhinitis, offers the advantage of OD treatment, and is well tolerated.
-
Once‐daily Mometasone Furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an active‐ and placebo‐controlled study
Allergy, 1996Co-Authors: Jacques Hebert, Keith B Nolop, Barry N. LutskyAbstract:Mometasone Furoate aqueous nasal spray (Nasonex) was compared with beclomethasone dipropionate (BDP) aqueous nasal spray in a double-blind, randomized, placebo-controlled, double-dummy, parallel-group study of adults with moderate to severe seasonal allergic rhinitis. Patients allergic to at least one tree and/or grass aeroallergen received one of the following regimens for up to 4 weeks; Mometasone Furoate 100 micrograms once daily [OD] (n = 126) or 200 micrograms OD (n = 126), BDP 200 micrograms twice daily (n = 126), or only placebo spray (n = 123). Physician-rated nasal and total symptom scores, and global evaluation of overall condition and therapeutic response by physicians and patients, showed that the three active treatments were equally effective, and all three were significantly superior to placebo at most time points. Overall, Mometasone Furoate 200 micrograms OD demonstrated somewhat greater numerical, but not statistical, superiority to Mometasone Furoate 100 micrograms OD at the earliest evaluation time point. At the end of treatment, complete or marked relief was obtained in 77% of patients with Mometasone Furoate 100 micrograms/day, 79% with Mometasone Furoate 200 micrograms/day, and 74% with BDP, compared with 54% of placebo vehicle control patients. Mometasone Furoate and BDP were equally well tolerated. It was concluded that Mometasone Furoate adequately controls symptoms of moderate to severe seasonal allergic rhinitis, offers the advantage of OD treatment, and is well tolerated.
Carmen Salavastru - One of the best experts on this subject based on the ideXlab platform.
-
Mometasone Furoate 0.1% and salicylic acid 5% vs. Mometasone Furoate 0.1% as sequential local therapy in psoriasis vulgaris.
Journal of the European Academy of Dermatology and Venereology : JEADV, 2009Co-Authors: George-sorin Tiplica, Carmen SalavastruAbstract:Abstract Background and objective Treatment in psoriasis vulgaris continues to unmet needs in terms of efficacy, quality of life and costs. Patients with moderate forms of psoriasis are using topical corticosteroids as first-line therapy and patients with severe forms also use this therapy. Optimization of this treatment is made by the use of combination drugs or by the sequential or rotational therapies. A multicentric clinical study was performed to measure the efficiency of Mometasone Furoate 0.1% and salicylic acid 5% and Mometasone Furoate 0.1% as sequential local therapy in psoriasis. Methods This was a randomized, multicentre trial with two patient groups receiving active treatment. The study group (N = 184) received Mometasone Furoate 0.1% and salicylic acid 5% for the first 7 days of treatment, and in the following 14 days, the patients used Mometasone Furoate 0.1%. The second group (N = 176) was treated with Mometasone Furoate 0.1% for 21 consecutive days. Psoriasis Area Severity Index (PASI) score and Dermatology Life Quality Index (DLQI) were calculated. Results After the first week of treatment in the study group, the reduction of PASI score was 44%, statistically significant greater than the reduction of PASI score in the second group (37%). Quality of life estimated by DLQI indicated significant lower values in the first (study) group. Conclusion The sequential treatment Mometasone Furoate 0.1% and salicylic acid 5% followed by Mometasone Furoate 0.1% proves to be efficient, safe and an excellent option for the following sequence: in-patient and out-patient. Conflict of Interest None declared.
Cynthia Guzzo - One of the best experts on this subject based on the ideXlab platform.
-
Mometasone Furoate 0.1%—salicylic acid 5% ointment versus Mometasone Furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study
Clinical therapeutics, 1998Co-Authors: John Koo, Cynthia A. Cuffie, Daniel J. Tanner, Renie Bressinck, Roger C. Cornell, Richard L. Devillez, Libby Edwards, Debra L. Breneman, Daniel Piacquadio, Cynthia GuzzoAbstract:Topical corticosteroids and keratolytics are both used widely in the management of patients with psoriasis. A combination of the two types of agents may provide enhanced relief. The purpose of this study was to compare the efficacy and safety of the combination ointment Mometasone Furoate 0.1% plus salicylic acid 5% with that of Mometasone Furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis vulgaris. A total of 408 patients were enrolled in this controlled, randomized, double-masked, parallel-group, multicenter comparison. Patients applied either Mometasone Furoate-salicylic acid ointment or Mometasone Furoate ointment alone to target lesions twice daily for 21 days. Severity of erythema, induration, and scaling were scored at baseline and at days 4, 8, 15, and 22. An evaluation of overall change in disease status of all treated lesions was performed at each follow-up visit. Adverse events were also monitored and scored, including signs of skin atrophy. Beginning on day 8, the combination of Mometasone Furoate-salicylic acid was significantly more effective than Mometasone Furoate alone, as indicated by the mean percentage of improvement in total disease scores, mean total disease sign scores, and the individual score for scaling. Similarly, the combination was more effective beginning on day 15, as indicated by the global evaluation of overall clinical response and individual scores for erythema and induration. Both treatments were well tolerated. Mometasone Furoate-salicylic acid ointment provides more effective treatment of moderate-to-severe psoriasis than does Mometasone Furoate ointment alone and is safe and well tolerated.
George-sorin Tiplica - One of the best experts on this subject based on the ideXlab platform.
-
Mometasone Furoate 0.1% and salicylic acid 5% vs. Mometasone Furoate 0.1% as sequential local therapy in psoriasis vulgaris.
Journal of the European Academy of Dermatology and Venereology : JEADV, 2009Co-Authors: George-sorin Tiplica, Carmen SalavastruAbstract:Abstract Background and objective Treatment in psoriasis vulgaris continues to unmet needs in terms of efficacy, quality of life and costs. Patients with moderate forms of psoriasis are using topical corticosteroids as first-line therapy and patients with severe forms also use this therapy. Optimization of this treatment is made by the use of combination drugs or by the sequential or rotational therapies. A multicentric clinical study was performed to measure the efficiency of Mometasone Furoate 0.1% and salicylic acid 5% and Mometasone Furoate 0.1% as sequential local therapy in psoriasis. Methods This was a randomized, multicentre trial with two patient groups receiving active treatment. The study group (N = 184) received Mometasone Furoate 0.1% and salicylic acid 5% for the first 7 days of treatment, and in the following 14 days, the patients used Mometasone Furoate 0.1%. The second group (N = 176) was treated with Mometasone Furoate 0.1% for 21 consecutive days. Psoriasis Area Severity Index (PASI) score and Dermatology Life Quality Index (DLQI) were calculated. Results After the first week of treatment in the study group, the reduction of PASI score was 44%, statistically significant greater than the reduction of PASI score in the second group (37%). Quality of life estimated by DLQI indicated significant lower values in the first (study) group. Conclusion The sequential treatment Mometasone Furoate 0.1% and salicylic acid 5% followed by Mometasone Furoate 0.1% proves to be efficient, safe and an excellent option for the following sequence: in-patient and out-patient. Conflict of Interest None declared.
John Koo - One of the best experts on this subject based on the ideXlab platform.
-
investigator masked comparison of tazarotene gel q d plus Mometasone Furoate cream q d vs Mometasone Furoate cream b i d in the treatment of plaque psoriasis
International Journal of Dermatology, 2001Co-Authors: John Koo, Dale MartinAbstract:Seventy-three patients with stable plaque psoriasis entered an investigator-masked trial comparing once-daily tazarotene 0.1% gel plus once-daily Mometasone Furoate 0.1% cream with twice-daily Mometasone Furoate 0.1% cream. The aim of the study was to determine whether tazarotene and Mometasone Furoate act synergistically –- a previous study showed that tazarotene plus Mometasone Furoate offered greater efficacy than tazarotene alone, and this study investigated whether tazarotene plus Mometasone Furoate also offered greater efficacy than Mometasone Furoate alone. The patients had psoriasis affecting up to 20% of their total body surface area, with at least moderate plaque elevation. Washout periods were: 2 weeks for UVB phototherapy or topical antipsoriatic therapies; 4 weeks for psoralen plus UVA (PUVA) therapy or systemic antipsoriatic drugs other than retinoids; and 8 weeks for oral retinoids. All patients gave written informed consent and the study was conducted in compliance with the ethical standards of the governing institutional review boards and the Declaration of Helsinki. Patients were treated for up to 12 weeks. If they achieved clearance by week 4, or at least 50% global improvement by week 12, they were entered into the 12-week no-treatment follow-up phase. Patients were evaluated every 4 weeks in terms of percentage global improvement, plaque elevation, scaling, erythema, and pruritus. They also rated the efficacy of their own treatment (as very effective, effective, neutral, ineffective, or less effective) and the duration of improvement in their psoriasis (as much better, better, somewhat better, indifferent, or worse than that achieved with other topical medications they had used in the past). The two regimens were compared by analysis of variance, with the last recorded score for any patient who discontinued prematurely (due to lack of efficacy, adverse events, or disease flare) being carried forward to all subsequent visits.
-
Investigator‐masked comparison of tazarotene gel q.d. plus Mometasone Furoate cream q.d. vs. Mometasone Furoate cream b.i.d. in the treatment of plaque psoriasis
International journal of dermatology, 2001Co-Authors: John Koo, Dale MartinAbstract:Seventy-three patients with stable plaque psoriasis entered an investigator-masked trial comparing once-daily tazarotene 0.1% gel plus once-daily Mometasone Furoate 0.1% cream with twice-daily Mometasone Furoate 0.1% cream. The aim of the study was to determine whether tazarotene and Mometasone Furoate act synergistically –- a previous study showed that tazarotene plus Mometasone Furoate offered greater efficacy than tazarotene alone, and this study investigated whether tazarotene plus Mometasone Furoate also offered greater efficacy than Mometasone Furoate alone. The patients had psoriasis affecting up to 20% of their total body surface area, with at least moderate plaque elevation. Washout periods were: 2 weeks for UVB phototherapy or topical antipsoriatic therapies; 4 weeks for psoralen plus UVA (PUVA) therapy or systemic antipsoriatic drugs other than retinoids; and 8 weeks for oral retinoids. All patients gave written informed consent and the study was conducted in compliance with the ethical standards of the governing institutional review boards and the Declaration of Helsinki. Patients were treated for up to 12 weeks. If they achieved clearance by week 4, or at least 50% global improvement by week 12, they were entered into the 12-week no-treatment follow-up phase. Patients were evaluated every 4 weeks in terms of percentage global improvement, plaque elevation, scaling, erythema, and pruritus. They also rated the efficacy of their own treatment (as very effective, effective, neutral, ineffective, or less effective) and the duration of improvement in their psoriasis (as much better, better, somewhat better, indifferent, or worse than that achieved with other topical medications they had used in the past). The two regimens were compared by analysis of variance, with the last recorded score for any patient who discontinued prematurely (due to lack of efficacy, adverse events, or disease flare) being carried forward to all subsequent visits.
-
Mometasone Furoate 0.1%—salicylic acid 5% ointment versus Mometasone Furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study
Clinical therapeutics, 1998Co-Authors: John Koo, Cynthia A. Cuffie, Daniel J. Tanner, Renie Bressinck, Roger C. Cornell, Richard L. Devillez, Libby Edwards, Debra L. Breneman, Daniel Piacquadio, Cynthia GuzzoAbstract:Topical corticosteroids and keratolytics are both used widely in the management of patients with psoriasis. A combination of the two types of agents may provide enhanced relief. The purpose of this study was to compare the efficacy and safety of the combination ointment Mometasone Furoate 0.1% plus salicylic acid 5% with that of Mometasone Furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis vulgaris. A total of 408 patients were enrolled in this controlled, randomized, double-masked, parallel-group, multicenter comparison. Patients applied either Mometasone Furoate-salicylic acid ointment or Mometasone Furoate ointment alone to target lesions twice daily for 21 days. Severity of erythema, induration, and scaling were scored at baseline and at days 4, 8, 15, and 22. An evaluation of overall change in disease status of all treated lesions was performed at each follow-up visit. Adverse events were also monitored and scored, including signs of skin atrophy. Beginning on day 8, the combination of Mometasone Furoate-salicylic acid was significantly more effective than Mometasone Furoate alone, as indicated by the mean percentage of improvement in total disease scores, mean total disease sign scores, and the individual score for scaling. Similarly, the combination was more effective beginning on day 15, as indicated by the global evaluation of overall clinical response and individual scores for erythema and induration. Both treatments were well tolerated. Mometasone Furoate-salicylic acid ointment provides more effective treatment of moderate-to-severe psoriasis than does Mometasone Furoate ointment alone and is safe and well tolerated.